Gleevec, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML ). In June 2006, a Phase I clinical trial found gleevec has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec®), another tyrosine kinase inhibitor currently used as a first-line treatment.
Gleevec is a transduction inhibitor that targets BCR-ABL, c-kit and PDGF, for the potential treatment of various leukemias, including chronic myeloid leukemia (CML).
Strength: 400 Mg
Pill Imprint: 400 SL SL
Shape: Elliptical / Oval
View Images & Details